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Abstract
Purpose of review—The primary purpose is to review guidance on the testing and treatment of 
latent tuberculosis infection (LTBI) in children. Most children and adults with LTBI have positive 
tuberculin skin test (TST) or interferon gamma release assay (IGRA) results, normal examinations, 
and normal chest radiographs. Diagnosis of and treatment completion for LTBI are critical to 
diminish future cases of tuberculosis (TB) disease.
Recent findings—Children should be screened for TB risk factors, and only children with risk 
factors should be tested with either a TST or an IGRA. IGRAs measure interferon gamma 
production by lymphocytes after they are stimulated ex vivo by antigens that are primarily 
Mycobacterium tuberculosis-specific. The foundation of LTBI therapy in the United States has 
been 9 months of daily isoniazid, but shorter treatment regimens now exist, including a 12-dose 
regimen of weekly isoniazid and rifapentine. These shorter regimens are associated with higher 
completion rates.
Summary—There are two distinct modalities for LTBI diagnosis and several treatment regimens 
that can prevent TB disease in infected children. The selection of treatment regimen should take 
several factors into consideration, including adherence, drug susceptibility results of the presumed 
source case (if known), safety, cost, and patient preference.
Keywords
interferon gamma release assay; latent tuberculosis infection; targeted testing; tuberculosis 
prevention
Correspondence to Mark N. Lobato, Connecticut Department of Public Health – TB Control Program, 410 Capitol Avenue, Mail Stop 
11-TUB, P.O. Box 340308, Hartford, CT 06134-0308, USA. Tel: +1 860 5097687; ; Email: mark.lobato@ct.gov 
Conflicts of interest
There are no conflicts of interest.
The opinions and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers 
for Disease Control and Prevention.
HHS Public Access
Author manuscript
Curr Opin Pediatr. Author manuscript; available in PMC 2016 June 07.
Published in final edited form as:














Children comprise a minority of tuberculosis (TB) patients [1]. The risk of progression from 
latent tuberculosis infection (LTBI) to TB disease is greatest in infants, decreases when 
children are 5–10 years of age, and increases during adolescence [2,3]. The probability of 
TB disease developing can be reduced substantially with treatment. In the United States, the 
majority of pediatric TB cases are attributable to healthcare providers missing opportunities 
for prevention [4▪▪,5]. Missed opportunities include not testing children with TB risk factors 
for LTBI and not initiating or completing treatment in children who are diagnosed with 
LTBI. Diagnosis of and treatment completion for LTBI are essential components of the 
strategy to eliminate TB [6].
This review is intended to update general practitioners, including primary care pediatricians, 
on the fundamentals of preventing TB by diagnosing and treating LTBI. It will consider risk 
factors for LTBI; new options for LTBI diagnosis; new treatment regimens for preventing 
TB disease; frequency of, and monitoring for, adverse events; barriers to treatment initiation 
and completion; and strategies to increase adherence with LTBI therapy. Treatment of HIV-
infected children with LTBI and of children infected after contact with persons with 
multidrug-resistant (MDR)-TB will not be discussed in detail because it is recommended 
that their management be done in consultation with an expert in pediatric TB.
PREDICTIVE FACTORS FOR MYCOBACTERIUM TUBERCULOSIS 
INFECTION
Associations with infection by Mycobacterium tuberculosis are well established [2]. Testing 
children who are unlikely to be infected gives poor predictive value of positive results. Thus, 
the American Academy of Pediatrics (AAP) does not recommend universal testing for LTBI. 
The dominant factors associated with LTBI among children in the United States are birth in 
or travel to a high-incidence country and being a contact of a household member with a 
history of LTBI or TB disease [7]. A simple screening tool incorporating these questions has 
been validated for LTBI screening in diverse community settings [8,9]. As the number of 
risks present increases, the tool becomes more specific and the positive predictive value of 
test results increases. Children with at least one factor associated with LTBI should be 
tested. However, one study indicated that a minority of pediatric providers use a 
standardized questionnaire among school-aged children [10]. More recently, association 
with parental birth abroad was reported for US-born children with TB [4▪▪]. This 
characteristic has yet to be prospectively validated, and is not usually included in screening 
questionnaires.
It is important to distinguish which children with LTBI have a high risk of progressing to TB 
disease. In contrast to the epidemiologic risk factors for acquisition of infection, the factors 
related to progression to disease are primarily associated with immunologic status: age 
younger than 5 years, M. tuberculosis infection within the past 2 years, and those factors 
also affecting adults, for example, HIV infection or other immunocompromising conditions 
or receipt of immunosuppressive medications [7].
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OPTIONS FOR LATENT TUBERCULOSIS INFECTION TESTING
Two options exist for the diagnosis of LTBI: the tuberculin skin test (TST) and IGRAs 
(Table 1) [11▪,12]. No reference standard currently exists for LTBI diagnosis, and, therefore, 
the pretest probability of infection and studies in children who have TB disease are used for 
estimating the sensitivity of these tests for LTBI and their predictive values [13▪▪]. TSTs are 
interpreted according to the individual’s risk profile. The amount of induration in 
millimeters considered positive optimizes sensitivity for children at highest risk of 
progression to TB disease and improves specificity for children who are less likely to have 
been infected (Table 1) [13▪▪]. In a low-risk population, the vast majority of positive TSTs in 
children without a risk factor will be false-positive results, emphasizing the need to focus 
LTBI screening on those with an associated factor for LTBI in order to lessen unnecessary 
tests and treatment. For these reasons, policies that promote universal testing of persons 
(e.g., all children entering school) without a factor associated with infection should be 
discouraged.
IGRAs are blood tests that detect interferon gamma released by lymphocytes ex vivo after 
stimulation with overlapping peptide sequences that simulate M. tuberculosis-specific 
antigens. These peptide sequences have antigenic homology with three nontuberculous 
pathogenic mycobacterial species – M. kansasii, M. marinum, and M. szulgai – but the 
clinical significance of the potential cross-reaction has not been determined. IGRAs offer 
several advantages over the TST, including superior specificity for patients who are 
sensitized to purified protein derivative tuberculin antigens because of bacille Calmette–
Guérin (BCG) vaccination or infection with a nontuberculous mycobacterium, for example, 
M. avium; a single definition for test positivity, and the need for only one healthcare 
encounter. Situations in which IGRAs are the preferred test for diagnosing LTBI in children 
are summarized in Table 2 [13▪▪,14]. One group in whom IGRAs may be of particular use is 
BCG-vaccinated children. The current generation of IGRAs was designed to take advantage 
of antigens that are present in M. tuberculosis complex, including wild-type M. bovis, but 
absent in BCG, which is prepared from attenuated strains of M. bovis. BCG vaccination 
diminishes TST specificity because of cross-reactive antigens, with complex interactions 
between the age at vaccination, the interval between vaccination and TST, the number of 
BCG doses, and the timing between TSTs (i.e., the skin test ‘boosting’ phenomenon) 
[15,16]. In studies to date, BCG vaccination has not been found to influence IGRA results.
Two commercial IGRA testing systems, Quanti-FERON-TB Gold (Qiagen) and T-SPOT.TB 
(Oxford Immunotec) are licensed by the US Food and Drug Administration for sale. Neither 
Centers for Disease Control and Prevention (CDC) nor the AAP recommends one IGRA 
over another [13▪▪,14]. IGRA incorporation into existing screening protocols in pediatric 
offices has been limited by insufficient data available in preschool-aged children, by the 
need for venipuncture and training on specimen handling, and by the incomplete market 
penetration of IGRAs. Another limiting factor is that indeterminate results for IGRA of up to 
24% have been reported in children less than 5 years of age [17,18], reducing its utility as a 
diagnostic test in this population.
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Focused testing of individuals with a risk for infection with M. tuberculosis is a more cost-
effective strategy than universal screening; however, there is no consensus on which test to 
use, TST or IGRA [19]. One group for which testing is mandated is adults applying for 
resident immigrant status and their children at least 2 years of age. Both adults and children 
are required to have a TST or an IGRA done at the overseas health screening site, and those 
with positive test results are further required to have a chest radiograph (CXR) done.
TREATMENT REGIMENS
Children with positive TST or IGRA results must be evaluated for TB disease prior to 
initiation of treatment for LTBI. The evaluation should include a CXR and a thorough 
physical examination, with particular attention to peripheral lymphadenopathy, and possibly 
collection of specimens for acid-fast bacillus staining, mycobacterial culture, and drug 
susceptibility testing. If TB disease is suspected or the primary care physician cannot 
manage LTBI diagnosis and treatment, the child should be referred to the health department 
or a pediatrician familiar with TB, for evaluation and treatment.
Once TB disease has been excluded, the provider can discuss LTBI treatment options with 
the family. Historically, the approach to LTBI therapy in the United States has been 
monolithic, relying upon isoniazid (isonicotinylhydrazine, INH) in all but a few select 
clinical situations. Data supporting non-isoniazid-based regimens have largely been derived 
from studies in adults. The decision as to which regimen to use should take adherence, drug 
susceptibility results of the presumed source case (if known), safety, cost, and patient 
preference into consideration [2]. Children at high risk of TB disease may be candidates for 
directly observed therapy (DOT), in which a healthcare worker or other trained person 
watches a patient swallow each dose of medication. DOT is one of the few interventions to 
be associated with improved treatment adherence [20]. In Houston, twice weekly LTBI 
therapy via DOT was shown to be effective in a cohort of over 400 children [21]. Other 
effective strategies include calendars for parental monitoring, treatment with incentives in 
the form of small toys or books provided to the child [22], school-based DOT [23], and 
adherence coaching for adolescents [24].
The current standard of practice in the United States for treating LTBI is 9 months of daily 
INH, unless documented resistance to INH is shown in the source case. INH is bactericidal 
and it is highly efficacious if taken as indicated. The chief problem with this regimen is that 
adherence with a 9-month regimen is poorer than with shorter regimens, limiting 
effectiveness.
A 4-month course of rifampin has been shown to be less costly, better tolerated, and more 
likely to be completed in adults than 9 months of INH [25]; the current AAP 
recommendation is a 6-month course [14], but no study has ever used this regimen. A course 
of treatment using rifampin is recommended when the child is known to be exposed to an 
infectious person with an INH-resistant strain or is intolerant to INH [14]. Rifampin is well 
tolerated by children [26], and the 4-month course probably will result in improved 
adherence but needs further study.
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A shorter course regimen, a 3-month combination of daily INH and rifampin, has been 
shown to be successful in children and associated with good adherence in the United 
Kingdom [27], although this regimen has not been included in guidelines for the United 
States. Rifapentine, a longer-acting rifamycin, can be administered once weekly in 
combination with INH. A recent landmark study indicated that 12 weekly doses of INH and 
rifapentine was noninferior to 9 months of INH in persons at least 12 years of age and had 
higher completion rates [28▪▪]. This is now a CDC-recommended regimen [29]. As with all 
intermittent dosing of TB medication (intermittent dosing can be once, twice or thrice 
weekly), this combination therapy is recommended only via DOT, as even one missed dose 
results in an almost 10% dose reduction. Follow-up of a cohort of younger children (2–11 
years old) is ongoing. To date, this regimen also appears to be well tolerated and safe in this 
age group [30].
For children less than 12 years of age, the preferred regimen remains 9 months of INH until 
further data and experience are available. However, certain scenarios may warrant the use of 
4 months of daily rifampin or 3 months of weekly INH/rifa pentine. These situations are 
discussed in Table 3 [14,31]. For adolescents, 3 months of weekly INH/rifapentine given by 
DOT may be considered, especially when adherence is questionable. For families who can 
afford the cost of rifampin (or for regions where LTBI therapy is provided free to children), 
4 months of rifampin may be the next best alternative to 9 months of INH for school-aged 
children and adolescents for whom INH/rifapentine is not available.
One important scenario relates to children with LTBI for whom immunosuppressive therapy 
[e.g., tumor necrosis factor-α (TNF-α) antagonists] has been or will be initiated by the 
child’s specialist. Although it is optimal to complete as much of the LTBI course as possible 
prior to the child becoming immunosuppressed, this is not always possible. At a minimum, 
expert opinion for the treatment of adults is that 4 weeks of LTBI therapy should be taken 
prior to initiating immunosuppression. This is a circumstance under which shorter course 
regimens would be preferable, so that a larger percentage of therapy can be completed prior 
to initiation of immunosuppression. However, clinicians must first be sure that the rifampin 
or rifapentine does not interact with any other medications, because rifamycins are potent 
inducers of cytochrome P450 enzymes that catalyze the oxidation of other drugs.
ADVERSE DRUG EVENTS
Most children tolerate TB medications far better than adults, and serious adverse events are 
rare [2]. Consequently, baseline and serial laboratory evaluation are unnecessary for the 
otherwise healthy child who is not receiving other potentially hepatotoxic medications. 
Asymptomatic increases of serum transaminase concentrations (two to three times the upper 
limit of normal) are common in children and have no clinical significance; thus, routine 
measurement of transaminase concentrations may result in further unnecessary testing, 
unnecessary treatment interruptions, or cessation of therapy if mild increases are noted. 
Measuring baseline serum transaminase concentrations is reasonable for children and 
adolescents having HIV infection, receiving medications that may potentially interact with 
TB medication, having underlying or recent hepatic or biliary disease, or being pregnant or 
in the first 6 weeks postpartum.
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Children should be followed up regularly by providers. Although monthly visits are strongly 
preferred and recommended, this may not be feasible for some families. At all visits, parents 
should be given written instructions and informed of possible adverse events so that they 
will know to stop administering medications if such events are observed. Lack of parental 
education about adverse events and failure to seek timely care might contribute to severe 
hepatotoxicity and other adverse drug effects [32]. In consideration of drug-induced liver 
injury, it is reasonable to interrupt the treatment regimen and promptly evaluate a child (by 
physical examination and laboratory evaluation) who has anorexia, nausea and vomiting, or 
abdominal pain. Signs and symptoms of hepatic toxicity should prompt immediate 
medication cessation with thorough relevant laboratory testing, including hepatic 
transaminases and bilirubin (conjugated and unconjugated). For children with a serum 
transaminase concentration, with or without symptoms, great enough to warrant stopping 
treatment or hyperbilirubinemia, additional testing should be done in consultation with an 
expert in pediatric TB. In addition, tests for agents causing viral hepatitis should be obtained 
because these pathogens remain a common cause of hepatic dysfunction.
Suspected drug-associated urticaria or more severe systemic reactions should prompt 
immediate cessation of the drug(s) and change to a different regimen after symptom 
improvement. A history of exposure to other medications, new foods, detergents, soaps, and 
skin lotions should be obtained. In children receiving other medications, clinicians should 
verify that the selected LTBI regimen will not result in major drug–drug interactions. 
Isoniazid is known to possibly affect anticoagulant agents, some anticonvulsants, 
benzodiazepines, and other classes of drugs. Rifampin interacts with multiple classes of 
drugs, including several antiepileptics, antifungals, antiretrovirals, hormonal contraceptives 
(e.g., birth control pills), and immunosuppressants.
BARRIERS TO COMPLETION OF THERAPY AND STRATEGIES FOR 
IMPROVING ADHERENCE
At least one-half of children who begin LTBI therapy with the 9-month INH regimen 
successfully complete treatment [20,33]. Most treatment default occurs in the first couple of 
months. There have been several studies attempting to outline characteristics of families of 
children who complete and those who fail to initiate or complete LTBI treatment. Adherence 
has been associated with greater TB knowledge, convenient appointment times [34], having 
a medical home [35], being of African or Latin American origin [33], self-selection of the 
treatment regimen, and promptly seeing a provider after having a positive TST result [23]. 
Nonadherence was associated with believing that taking medication would be challenging, 
and with having been previously recommended for LTBI treatment, and was more common 
in children of families from eastern Europe and Asia [33]. A recent study found that the only 
factor associated with successful completion of LTBI treatment was administration of 
medications by local health departments through DOT [20]. In this study, completion of 
therapy was approximately 50% when families administered medication, in contrast to 
greater than 95% when workers from the health department administered medication via 
DOT.
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A less resource-intense alternative to DOT is enhanced self-administered therapy (ESAT). 
ESAT programs provide medication to families monthly, with periodic phone calls to remind 
families about adherence and to ask about adverse events. The rate of completion of LTBI 
therapy using INH was 86% using ESAT in one cohort [20].
To improve treatment completion, practitioners need to routinely use measures to enhance 
adherence. Some measures may be best carried out in partnership with local health 
departments. Children at high risk for progression to disease are candidates for DOT. 
However, DOT is a limited resource in many settings. Other strategies to increase familial 
adherence are listed in Table 4. Administration of LTBI therapy through school-based clinics 
[23] or through extended-hour community-based clinics [35] has been shown to improve 
completion of therapy. From a practical standpoint, if a child completes at least 6 months of 
isoniazid before defaulting, therapy may be considered completed, as it is unlikely the 
family will be interested in restarting a course of therapy, and a 6-month course of daily INH 
is known to have intermediate efficacy, at least for adults [36]. However, if INH is chosen, 9 
months of therapy should be the goal.
CONCLUSION
There are two modalities for diagnosing LTBI, as well as several effective treatment 
regimens, which can be used for infected children. The first step in screening children and 
adolescents is a risk factor assessment. Diagnostic tests should optimize sensitivity in 
children at risk for rapid progression to disease (e.g., infants, recently infected, 
immunocompromised) and optimize specificity for children with fewer risk factors or 
vaccination with BCG, thereby decreasing the number of uninfected children receiving 
therapy. If LTBI is diagnosed, the decision as to which AAP/CDC-recommended regimen to 
use should consider adherence factors and factors that may limit the choice of medications.
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• Use of a standardized questionnaire to select children for testing based on 
assessment of established factors associated with TB focuses on children with 
the highest risk for having LTBI and possible progression to TB disease.
• Use of IGRAs, with their improved specificity particularly for children who 
have received the BCG vaccine, may decrease the number of uninfected children 
receiving therapy and enable limited resources to be focused on children who 
would benefit the most from therapy.
• Multiple LTBI treatment regimens have been studied to varying degrees: 
selection of regimen should take efficacy, adherence, family preference, possible 
side-effects, cost, and availability of DOT into consideration.
• Children at the highest risk for progression to TB disease should be considered 
candidates for DOT to optimize adherence. For children for whom DOT is 
unavailable, adherence may be increased by incentives and enablers.
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Table 1
Immunogenic comparison of the tuberculin skin test and the interferon gamma release assay in children and 
interpretation of test results
Variable TST IGRA











Requires experience in clinical
  interpretation
Yes Yes
Risk of having boosted reaction Yes Noc
Distinguishes TB disease from
  LTBI
No No
Single cut-off for positivity No Yes
TST cut-offs by risk factors Yes
≥5 mm Immunocompromised, contact with TB
  case, suspected of having TB disease,
  children with fibrotic changes on CXR
  consistent with prior disease
Single cut-off for positivity regardless of
  age,d epidemiologic risk factors,
  comorbidities, or concern for TB
  disease
≥10 mm Children <4 years of age, children
  exposed to high-risk adults,e recent
  (<5 years) immigrants from high-incidence
  countries,f and some chronic
  medical conditions (e.g., diabetes)
≥15 mm Positive regardless of risk factors
BCG, bacille Calmette–Guérin; CXR, chest radiograph; IGRA, interferon gamma release assay; LTBI, latent tuberculosis infection; NTM, 
nontuberculous mycobacteria; TB, tuberculosis; TST, tuberculin skin test.
a
Possible cross-reaction with M. kansasii, M. marinum, and M. szulgai.
b
Sensitivity data are extracted from two pediatric meta-analyses of children with TB disease.
c
Evidence exists suggesting that the TST, especially in IGRA-negative persons, can boost the IGRA result if the TST is administered more than 3 
days prior to an IGRA.
d
T-SPOT. TB has a borderline result between negative and positive.
e
High-risk adults: recent immigrants from high- prevalence countries, occupants of congregate settings (jails, nursing homes, homeless shelters, 
healthcare workers exposed to TB), HIV-infected, injection drug users.
f
High-incidence countries: countries outside the United States, Canada, Scandinavia, western Europe, Australia, and New Zealand. Adapted from 
[11▪, 12, 13▪▪].
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Table 2
Indications for preferred use of interferon gamma release assays or the tuberculin skin test for the diagnosis of 
latent tuberculosis infection in children
Preferred test Scenario
TST preferred, IGRA acceptable <5 years of age
IGRA preferred, TST acceptable BCG vaccinated
Unlikely to return for TST reading
Either TST or IGRA Recent contacts (≥5 years of age) of persons with confirmed or suspected TB disease
Periodic screening of persons with ongoing exposure (e.g., adolescents in correctional facilities)
Both IGRA and TSTa Initial TST or IGRA is negative in the following situations: the risk for infection, the risk for
  progression, or the risk for a poor outcome is increased (e.g., HIV infection, children <5 years
  old); additional evidence of infection is required to encourage adherence (e.g., persons who
  believe the positive TST result is attributable to BCG); in healthy persons who have a low risk
  for both infection and progression; or clinical suspicion exists for TB disease and confirmation
  of M. tuberculosis infection is desired
IGRA is indeterminate; an alternative to TST placement for children with one indeterminate IGRA
  is to obtain another IGRA result with the same testing product or the alternative product
Initial test is negative and the risk of progression to disease is high
IGRA, interferon gamma release assay; TB, tuberculosis; TST, tuberculin skin test.
a
In most cases, the child presents with a positive TST; children with suspected TB disease or nontuberculous mycobacterial disease are not 
included in this table. Adapted from [13▪▪, 14].
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Table 3
Selection of specific drug regimens given particular scenarios for the treatment of latent tuberculosis infection 
in children
Regimen Scenario Notes
INH Standard of practice Daily dosing
Medication provided intermittently Treatment must be given by DOT
Intolerant of rifampin Severe adverse drug effects much less common than in
  adults; hypersensitivity reactions occur in up to 4% of
  adults
Child is receiving medications which may interact with
  rifampin or rifapentine
An FDA-generated list of medications potentially
  interacting with rifampin is available at:
  http://www.accessdata.fda.gov/drugsatfd a_docs/label/
2013/050420s075,050627s014lbl.pdf
RIF Intolerant of INH Possible severe adverse reactions occur in <1% of
  children receiving INH. Fewer data exist for RIF
INH-resistant TB in a person in contact with a child,
  RIF-susceptible M. tuberculosis isolate
There are no data for intermittent dosing of rifampin for
  LTBI therapy in children
Short course is desirable, but INH+RPT is unavailable or
  not indicated (child <2 years of age)
Adherence is higher for short course regimens
INH+RPTa Adherence concerns No data are available for children <2 years of age
Short course is desirable or need to complete therapy
  urgently (e.g., prior to initiation of immunosuppressive
  therapy or if child will be traveling)
Scant data on optimal duration of therapy before
  beginning immunosuppression; many experts recommend
  at least 4 weeks
INH+RIF Short course is desirable, but INH+RPT is unavailable Administer dailyb
DOT, directly observed therapy; FDA, Federal Drug Administration; INH, isoniazid; RIF, rifampin; RPT, rifapentine; TB, tuberculosis.
a
Should only be administered under DOT; use may be limited by availability of rifapentine and/or DOT services.
b
This regimen has not been included in guidelines for the United States.
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Table 4
Potential barriers to the diagnosis and treatment of latent tuberculosis infection in children and adolescents and 
possible solutions to address these barriers
Stage Potential barrier Possible solution
Diagnosis
Lack of medical home Screen in nontraditional venues (e.g., schools)
Failure to return for TST reading Use an IGRA
Concern for false-positive results Use IGRAs; only test children with at least one TB risk factor
Concern for false-negative results Consider testing certain high-risk children by both the TST and
  the IGRA
Treatment
Failure to initiate therapy
  Family refuses to initiate Cannot mandate LTBI therapy; if families do not cite reason,
  document that risks/benefits explained to them
  Fail to understand importance of treatment Educate families on the age-related risk of disease progression in
  their preferred language
  Confusion about the effect of BCG on the TST Use an IGRA (Table 1)
  Cannot afford medication Discuss cost of medications with families before prescribing;
  inform them of least expensive locations to purchase
  medications; consider DOT
  Concern for adverse events Educate families on possible adverse events and frequency;
  preemptively address internet searching for medication
  information as most information will refer to adult data
  Concern for treatment duration Consider shorter treatment courses; understand what time
  constraints the family may be under
Default on therapy
  Fail to understand the importance of treatment Educate families; regular clinic visits to reinforce progress;
  consider DOT for children at risk for disease progression
  Cannot remember to take medication Consider use of DOT (including by school nurses); set cell phone
  alarms
BCG, bacille Calmette–Guérin; DOT, directly observed therapy; IGRA, interferon gamma release assay; TST, tuberculin skin test.
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